User login
The FDA recently widened the approved use of nanoparticle albumin bound (nab) paclitaxel (nab-paclitaxel) to include first-line treatment for non–small-cell lung cancer (NSCLC), in combination with carboplatin. This approval was based on results of a global, phase 3 randomized trial conducted by Socinski et al that compared the use of nab-paclitaxel and solventbased paclitaxel injection in combination with carboplatin as first-line treatment of advanced NSCLC.1 Taxanes are the most widely used chemotherapeutic agents in solid tumor oncology. Paclitaxel and docetaxel are effective in the treatment of NSCLC and are frequently used for adjuvant therapy after resection, in combination with radiation for locally advanced disease and for treatment of patients with advanced disease. They are usually used in combination with platinum agents or as single-agent therapy in the relapsed refractory setting. Paclitaxel and docetaxel require synthetic solvents for intravenous administration, which can cause life-threatening allergic reactions and significant toxicity. Nab-paclitaxel is a novel, solvent-free formulation of paclitaxel, which can be administered without the need for steroid and antihistamine premedication. Furthermore, nab-paclitaxel delivers high concentrations of the drug’s active ingredient into the cancer cell with a reduced incidence of side effects compared with the solvent-based formulation. As summarized in the Community Translations article on page 166, the administration of nab-paclitaxel as firstline therapy in combination with carboplatin was efficacious and resulted in a significantly improved overall response rate (ORR), compared with paclitaxel (33% vs 25%, respectively; response rate ratio [RRR], 1.313; 95% CI, 1.082-1.593; P .005), and it achieved the study’s primary end point. Of note, ORR was significantly greater with nab-paclitaxel in patients with squamous cell histology (41% vs 24%; RRR, 1.680; P .001), with no difference between treatments being observed in patients with nonsquamous histology (ORR, 26% vs 25%) or adenocarcinoma (ORR, 26% vs 27%). There was no difference in PFS or survival between the 2 arms.
The FDA recently widened the approved use of nanoparticle albumin bound (nab) paclitaxel (nab-paclitaxel) to include first-line treatment for non–small-cell lung cancer (NSCLC), in combination with carboplatin. This approval was based on results of a global, phase 3 randomized trial conducted by Socinski et al that compared the use of nab-paclitaxel and solventbased paclitaxel injection in combination with carboplatin as first-line treatment of advanced NSCLC.1 Taxanes are the most widely used chemotherapeutic agents in solid tumor oncology. Paclitaxel and docetaxel are effective in the treatment of NSCLC and are frequently used for adjuvant therapy after resection, in combination with radiation for locally advanced disease and for treatment of patients with advanced disease. They are usually used in combination with platinum agents or as single-agent therapy in the relapsed refractory setting. Paclitaxel and docetaxel require synthetic solvents for intravenous administration, which can cause life-threatening allergic reactions and significant toxicity. Nab-paclitaxel is a novel, solvent-free formulation of paclitaxel, which can be administered without the need for steroid and antihistamine premedication. Furthermore, nab-paclitaxel delivers high concentrations of the drug’s active ingredient into the cancer cell with a reduced incidence of side effects compared with the solvent-based formulation. As summarized in the Community Translations article on page 166, the administration of nab-paclitaxel as firstline therapy in combination with carboplatin was efficacious and resulted in a significantly improved overall response rate (ORR), compared with paclitaxel (33% vs 25%, respectively; response rate ratio [RRR], 1.313; 95% CI, 1.082-1.593; P .005), and it achieved the study’s primary end point. Of note, ORR was significantly greater with nab-paclitaxel in patients with squamous cell histology (41% vs 24%; RRR, 1.680; P .001), with no difference between treatments being observed in patients with nonsquamous histology (ORR, 26% vs 25%) or adenocarcinoma (ORR, 26% vs 27%). There was no difference in PFS or survival between the 2 arms.
The FDA recently widened the approved use of nanoparticle albumin bound (nab) paclitaxel (nab-paclitaxel) to include first-line treatment for non–small-cell lung cancer (NSCLC), in combination with carboplatin. This approval was based on results of a global, phase 3 randomized trial conducted by Socinski et al that compared the use of nab-paclitaxel and solventbased paclitaxel injection in combination with carboplatin as first-line treatment of advanced NSCLC.1 Taxanes are the most widely used chemotherapeutic agents in solid tumor oncology. Paclitaxel and docetaxel are effective in the treatment of NSCLC and are frequently used for adjuvant therapy after resection, in combination with radiation for locally advanced disease and for treatment of patients with advanced disease. They are usually used in combination with platinum agents or as single-agent therapy in the relapsed refractory setting. Paclitaxel and docetaxel require synthetic solvents for intravenous administration, which can cause life-threatening allergic reactions and significant toxicity. Nab-paclitaxel is a novel, solvent-free formulation of paclitaxel, which can be administered without the need for steroid and antihistamine premedication. Furthermore, nab-paclitaxel delivers high concentrations of the drug’s active ingredient into the cancer cell with a reduced incidence of side effects compared with the solvent-based formulation. As summarized in the Community Translations article on page 166, the administration of nab-paclitaxel as firstline therapy in combination with carboplatin was efficacious and resulted in a significantly improved overall response rate (ORR), compared with paclitaxel (33% vs 25%, respectively; response rate ratio [RRR], 1.313; 95% CI, 1.082-1.593; P .005), and it achieved the study’s primary end point. Of note, ORR was significantly greater with nab-paclitaxel in patients with squamous cell histology (41% vs 24%; RRR, 1.680; P .001), with no difference between treatments being observed in patients with nonsquamous histology (ORR, 26% vs 25%) or adenocarcinoma (ORR, 26% vs 27%). There was no difference in PFS or survival between the 2 arms.